TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06631664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A computerized electrical stimulator (Vectra®2C; Chattanooga, TS, USA)
Description: The patient was positioned in supine lying position with the affected arm beside the body and elbow extended, the skin over the anterior and posterior comportment of the upper arm was cleaned using medical cotton sacked in alcohol before the application.~The first two stimulating electrodes for the biceps muscle were placed at the superior and inferior 1/3 of anterior surface of the upper arm with a distance in between the two electrodes at least the size of one of them, while the other two electrodes for the triceps muscle were placed at the superior and inferior 1/3 of the posterior surface of the upper arm.~One millisecond pulse duration and a frequency of 50Hz with a rectangular shaped pulse were utilized and stimulation was applied for 15 minutes. At first a low-intensity current is applied and gradually increased till a gentle contraction of the muscles appears and allow time for the child to become accustomed to the current and maintained sufficient and observable contraction.
Study: NCT06630546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: first generation iStent (Glaukos, San Clemente, CA, USA) insertion
Description: In glaucoma patient who needed to receive cataract surgery, a standard phacoemulsification procedure was performed, along with the implantation of a foldable posterior chamber intraocular lens (PCIOL). Then, in adequate patient who wish to receive iStent insertion, we further inserted a preloaded micro-bypass stent (model GTS100L) through the temporal corneal incision into the nasal Schlemm's canal and checked the position. Adequate intraocular pressure (IOP) was assessed by palpation at the end of the surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification
Description: A standard phacoemulsification procedure was performed, along with the implantation of a foldable posterior chamber intraocular lens (PCIOL).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: phacoemulsification
Description: A standard phacoemulsification procedure was performed, along with the implantation of a foldable posterior chamber intraocular lens (PCIOL).
Study: NCT06632106

Intervention type: PROCEDURE
Intervention: hepatic artery infusion chemotherapy
Description: Hepatic arterial infusion chemotherapy including FOLFOX and RALOX

Intervention type: DRUG
Intervention: Tyrosine kinase inhibitor (TKIs)
Description: TKIs including Lenvatinib, Sorafenib, Apatinib, Donafenib, Bevacizumab

Intervention type: DRUG
Intervention: Tyrosine kinase inhibitor (TKIs)
Description: TKIs including Lenvatinib, Sorafenib, Apatinib, Donafenib, Bevacizumab

Intervention type: DRUG
Intervention: Immune Checkpoint Inhibitors
Description: ICIs including Camrelizumab, Sintilimab, Tislelizumab, Pembrolizumab, Atezolizumab

Intervention type: DRUG
Intervention: Immune Checkpoint Inhibitors
Description: ICIs including Camrelizumab, Sintilimab, Tislelizumab, Pembrolizumab, Atezolizumab
Study: NCT05869318

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECIG own
Description: Participants will vape using their own ecig device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECIG Vuse
Description: Participants will vape a VUSE e-cigarette (GOLD 5%)
Study: NCT06230159

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-menthol Cigarette Smoking
Description: Smoke a non-menthol cigarette

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Menthol Cigarette Smoking
Description: Smoke a menthol cigarette

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic Cooling Agent Cigarette Smoking
Description: Smoke a synthetic cooling agent cigarette

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Brand Cigarette Smoking
Description: Smoke usual brand cigarette

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Brand Cigarette Smoking
Description: Smoke usual brand cigarette

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Brand Cigarette Smoking
Description: Smoke usual brand cigarette

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Description: Pulmonary function test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Description: Pulmonary function test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Spirometry
Description: Pulmonary function test

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Survey questionnaires

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Survey questionnaires

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Survey questionnaires

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Epithelial Lining Fluid
Description: Nasal strip inserted into the nare to collect nasal epithelial lining fluid.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Epithelial Lining Fluid
Description: Nasal strip inserted into the nare to collect nasal epithelial lining fluid.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Epithelial Lining Fluid
Description: Nasal strip inserted into the nare to collect nasal epithelial lining fluid.
Study: NCT05040750

Intervention type: OTHER
Intervention: laboratory investigation
Description: observe the relation between cardiac markers and mortality rate in critically ill COVID 19 patients
Study: NCT06480123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Skin drug prepared with exome originated from stem cell
Description: Skin drug prepared with exome originated from stem cell will be applied to patient with diabetic foot.
Study: NCT04899284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Intensive Bimanual Stimulation
Description: Early intensive bimanual stimulation program for infants showing early signs of UCP, delivered by the family environment, in the child's familiar surroundings, under the guidance of a therapist, over a period of 2 months.
Study: NCT06211634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMB-001
Description: HMB-001 is a bispecific antibody being developed as a prophylactic treatment option to prevent and reduce bleeding events in patients with Glanzmann thrombasthenia.
Study: NCT06722664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Chymotrypsin(OsrhCT) 4000U
Description: Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/vial, freeze-dried powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Chymotrypsin(OsrhCT) 4000U
Description: Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/vial, freeze-dried powder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Recombinant Human Chymotrypsin(OsrhCT)
Description: Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 0 U/vial, freeze-dried powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Recombinant Human Chymotrypsin(OsrhCT)
Description: Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 0 U/vial, freeze-dried powder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dimethicone emulsion 4ml
Description: Dimethicone emulsion，produced by Sichuan Jian Neng Pharmaceutical Co., Ltd, 6ml/bottle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethicone emulsion 4ml
Description: Dimethicone emulsion，produced by Sichuan Jian Neng Pharmaceutical Co., Ltd, 6ml/bottle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethicone emulsion 4ml
Description: Dimethicone emulsion，produced by Sichuan Jian Neng Pharmaceutical Co., Ltd, 6ml/bottle.
Study: NCT06737380

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Physical examination
Description: The physical examination will be performed at the Screening visit and at each subsequent study and safety follow-up visit. The exam will include: measurement of vital signs (heart rate, peripheral arterial blood pressure, respiratory rate, and temperature), weight, height (at Screening visit only), cardiovascular and respiratory systems, abdominal examination, skin evaluation, mouth and eye evaluation, and neurological assessment. Abnormal findings will be recorded in the CRF.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: A twelve-lead electrocardiogram (ECG), including corrected QT interval (QTc interval), will be performed in all participants at the Screening visit and at the final visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SF-36 questionnaire
Description: Patients will fill out the SF 36 survey, assessing physical and mental health outcomes prior to dosing and/or any other clinical assessments, on visits 1 (baseline), visit 5 (day 14), visit 6 (day 28), visit 11 (day 168) and early termination visit.
Study: NCT05365490

Intervention type: PROCEDURE
Intervention: Transcarotid Artery Revascularization (TCAR)
Description: Carotid artery revascularization treated with the FDA-cleared ENROUTE Transcarotid NPS in conjunction with the FDA-approved ENROUTE Transcarotid Stent
Study: NCT05239533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-labeled-girentuximab
Description: The initial starting dose/Dose Level 1 of 177Lu-labeled-girentuximab is 1804 MBq/m2. if 0/3 or 1/6 DLTs, participants will be treated at Dose Level 2 177Lu-girentuximab 2405 MBq/m2. \>/= 2/6 DLTs, Dose Level -1 is 177Lu-girentuximab 1353 MBq/m2~Once the MTD is established, a Simon two-stage optimal design will commence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-labeled-girentuximab
Description: The initial starting dose/Dose Level 1 of 177Lu-labeled-girentuximab is 1804 MBq/m2. if 0/3 or 1/6 DLTs, participants will be treated at Dose Level 2 177Lu-girentuximab 2405 MBq/m2. \>/= 2/6 DLTs, Dose Level -1 is 177Lu-girentuximab 1353 MBq/m2~Once the MTD is established, a Simon two-stage optimal design will commence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240mg q2wk

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240mg q2wk

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 89Zr-girentuximab PET/CT
Description: All patients will undergo a 89Zr-girentuximab PET/CT scan prior to every 177Lu-girentuximab administration

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 89Zr-girentuximab PET/CT
Description: All patients will undergo a 89Zr-girentuximab PET/CT scan prior to every 177Lu-girentuximab administration

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 177Lu whole body (WB) planar and SPECT/CT scans
Description: 177Lu whole body (WB) planar and SPECT/CT scans will be performed after each administration of 177Lu-girentuximab
Study: NCT05239533

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 177Lu whole body (WB) planar and SPECT/CT scans
Description: 177Lu whole body (WB) planar and SPECT/CT scans will be performed after each administration of 177Lu-girentuximab
Study: NCT05062915

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HINTS
Description: HINTS (Head Impulse, Nystagmus, test of skew) V-HIT (Head impulse test google assisted) MRI: 3-4 MRI of the brain including the posterior fossa Vestibular rehabilitation for all patients with a vestibular deficit.
Study: NCT05994248

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enform Mesh
Description: Use of absorbable mesh in umbilical hernia repair
Study: NCT06738225

Intervention type: DIAGNOSTIC_TEST
Intervention: certain serum MicroRNA biomarkers (miR-15b and miR-21)
Description: miR-15b and miR-21 as diagnostic biomarkers of colorectal cancer

Intervention type: DIAGNOSTIC_TEST
Intervention: certain serum MicroRNA biomarkers (miR-15b and miR-21)
Description: miR-15b and miR-21 as diagnostic biomarkers of colorectal cancer
Study: NCT06743945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POLA-R-CHP
Description: Pola-R-CHP is a combination of rituximab, cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin
Study: NCT06747169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab, albumin-bound paclitaxel plus platinum agent (Nab-PP), and recombinant human endostatin
Description: All patients were treated with a combination therapy consisting of sintilimab, albumin-bound paclitaxel plus platinum agent (Nab-PP), and recombinant human endostatin. The study is designed to assess the efficacy and safety of this treatment regimen in the specified population.
Study: NCT06746636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High velocity nasal insufflation
Description: • HVNI was supplied using a Vapotherm Precision Flow \[Precision Flow Plus, Vapotherm, INC. U.S.A. device\].

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High velocity nasal insufflation
Description: • HVNI was supplied using a Vapotherm Precision Flow \[Precision Flow Plus, Vapotherm, INC. U.S.A. device\].

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High velocity nasal insufflation
Description: • HVNI was supplied using a Vapotherm Precision Flow \[Precision Flow Plus, Vapotherm, INC. U.S.A. device\].

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High velocity nasal insufflation
Description: • HVNI was supplied using a Vapotherm Precision Flow \[Precision Flow Plus, Vapotherm, INC. U.S.A. device\].
Study: NCT06747338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026
Description: KN026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB1801
Description: HB1801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Pertuzumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel
Study: NCT06748950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LCHF Ketogenic Diet
Description: Low Carbohydrate, Moderate Protein, High Fat (LCHF) Ketogenic Dietary Intervention for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LCHF Ketogenic Diet
Description: Low Carbohydrate, Moderate Protein, High Fat (LCHF) Ketogenic Dietary Intervention for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet-as-Usual (DAU)
Description: Participant's usual diet
Study: NCT06748781

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpectomy using 2.5% Calcium Hypochlorite root canal irrigant.
Description: 2.5% Calcium Hypochlorite used as root canal irrigant during the pulpectomy procedure in mandibular primary molars.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpectomy using Saline as root canal irrigant
Description: Saline used as root canal irrigant during the pulpectomy procedure in mandibular primary molars.
Study: NCT06750003

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3D versus 4K laparoscopic bilateral salpingo-oophorectomy
Description: 3D laparoscopy versus 4K laparoscopy for bilateral salpingo-oophorectomy performed by residents

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D versus 4K laparoscopic bilateral salpingo-oophorectomy
Description: 3D laparoscopy versus 4K laparoscopy for bilateral salpingo-oophorectomy performed by residents
Study: NCT04790929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muse
Description: Interaxon markets a head-worn EEG biofeedback device ('Muse') to encourage and aid effective meditation and sleep. This device has been previously shown to improve workplace wellness, fatigue and quality of life, and performance on the Stroop Task. It has also been shown to improve physiological markers associated with improved relaxation. Muse has been shown to have an EEG signal comparable to a clinical grade EEG.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muse
Description: Interaxon markets a head-worn EEG biofeedback device ('Muse') to encourage and aid effective meditation and sleep. This device has been previously shown to improve workplace wellness, fatigue and quality of life, and performance on the Stroop Task. It has also been shown to improve physiological markers associated with improved relaxation. Muse has been shown to have an EEG signal comparable to a clinical grade EEG.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Coaching
Description: Participants will be asked to use the Muse Meditation system for a minimum of 5 minutes a day (in one or multiple sessions), a minimum of 5 days a week, for 6 weeks and will be coached in how to do so. Coaches will be versed in Mindfulness and how to use Muse. Coaching will take place virtually using Interaxon's Zoom account.
Study: NCT04747509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blackburn exercises
Description: Experimental group will include Blackburn exercises and hot pack for 10 minutes prior to the application of exercises; 3 sessions/week for a total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. bilateral difference in lateral scapular slide test, serratus anterior and lower trapezius muscle strength, static measurements of scapula ROM, and pain and disability.~These exercises will include prone horizontal abduction neutral and with full external rotation, prone horizontal scaption neutral and with full external rotation, prone horizontal external rotation, prone horizontal extension. All these exercises will be performed 3x15 repetitions with 30 seconds rest interval between each set.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical therapy
Description: Control group will include conventional physical therapy and hot pack for 10 minutes prior to the application of exercises; 3 sessions/week for a total of 4 weeks. Measurement will be taken at base level and after the last session, i.e. bilateral difference in lateral scapular slide test, serratus anterior and lower trapezius muscle strength, static measurements of scapula ROM, and pain and disability.~These exercises will include push-ups on a stable surface, upward rotation shrugs and resisted scapular retraction. All these exercises will be performed 3x15 repetitions with 30 seconds rest interval between each set.
Study: NCT05781854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia with bupivacaine and dexmedetomidine
Description: Epidural analgesia with bupivacaine and dexmedetomidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia with bupivacaine and dexmedetomidine
Description: Epidural analgesia with bupivacaine and dexmedetomidine
Study: NCT05789264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Compression Device
Description: Participants assigned to the NasaClip arm will not receive routine care as the objective of this study is to compare the NasaClip device to routine digital compression in terms of feasibility, comfort, and efficacy. Limited data previously discussed in the background section indicates that application of nasal compression devices may be superior to digital compression.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Most first aid instructions for epistaxis management tell patients to apply firm digital pressure for 10 to 20 minutes, use a topical vasoconstrictor and apply an ice pack over the nose.
Study: NCT06751095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maitland's Mobilization in End range
Description: End-range mobilization will be performed individually in flexion and extension end range of the tibiofemoral joint .(0-135 degree)
Study: NCT05523063

Intervention type: OTHER
Intervention: Quality of life questionnaire
Description: The quality of life questionnaire will be performed in routine practice by the CAMI during the initial assessment.~The 3-month visit is part of the routine patient visit to CAMI. During this visit, the quality of life questionnaire will be completed a second time by the patients, through a phone call given by the investigator.
Study: NCT05041959

Intervention type: OTHER
Group type: OTHER
Intervention: Smoking Abstinence
Description: Participants will abstain from smoking for 24 hours

Intervention type: OTHER
Group type: OTHER
Intervention: Ad Lib Smoking
Description: Participants will continue smoking as usual (i.e. ad lib) in the day leading up to the scan and smoke one cigarette of their own brand immediately prior to scanning.
Study: NCT05366699

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: axillary lymphadenectomy with immediate lymphatic reconstruction (LYMPHA)
Description: lymphatic reconstruction where the cut lymphatic vessels are reconstructed by anastamosing to the veins
Study: NCT06751095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maitland's mobilization in Mid range
Description: Mid range Maitland's mobilization will be performed in (approx. 50-70° knee flexion) of the tibiofemoral joint